SCA
GMAB icon

Stuart Chaussee & Associates’s Genmab GMAB Stock Holding History

Stuart Chaussee & Associates’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-42
Closed -$1K – 188
2021
Q1 		$1K Buy
+42
New +$1.58K ﹤0.01% 236

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Stuart Chaussee & Associates's GMAB Position: Q2 2021 in Review

Stuart Chaussee & Associates sold out of Genmab (GMAB) in Q2 2021, closing a stake of 42 shares — an estimated $1K sold.

Stuart Chaussee & Associates first reported a position in GMAB in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 212 funds tracked by Wall St. Rank hold GMAB as of Q2 2021.

  • Stuart Chaussee & Associates reported no remaining Genmab position as of Q2 2021 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 42 Genmab shares in Q2 2021, an estimated $1K.
  • Stuart Chaussee & Associates first reported a position in Genmab in Q1 2021 and held it in 1 quarter.
  • Stuart Chaussee & Associates's Genmab position peaked at $1K in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Genmab as of Q2 2021.

Based on Stuart Chaussee & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.